Adefovir was invented in the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic by Antonín Holý, and the biologic was developed by Gilead Sciences for HIV with the cast name Preveon. However, in November 1999, an able console brash the U.S. Food and Biologic Administration (FDA) not to accept the biologic due to apropos about the severity and abundance of branch toxicity if dosed at 60 or 120 mg. The FDA followed that advice, abnegation to accept adefovir as a analysis for HIV.
Gilead Sciences discontinued its development for HIV analysis in December 1999, but connected to advance the biologic for hepatitis B (HBV), area it is able with a abundant lower dosage of 10 mg. FDA approval for use in the analysis of hepatitis B was accepted on September 20, 2002, and adefovir is awash for this adumbration beneath the cast name Hepsera. Adefovir became an accustomed analysis for HBV in the European Union in March 2003.